a public good project by the
Synthesis
Company
of California

© 2026

Maximilian von Eynatten | doi.page

0 works0 citations0 h-index

Maximilian von Eynatten

Nestlé (Switzerland)(CH)Nestlé Health Science (United States)

Publications by Year

Research Areas

Diabetes Treatment and Management, Diabetes Management and Research, Pancreatic function and diabetes, Chronic Kidney Disease and Diabetes, Metabolism, Diabetes, and Cancer

Most-Cited Works

→ Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes(2016)3,565 cited
→ Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus(2013)1,278 cited
→ Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk(2018)1,061 cited
→ A mechanism converting psychosocial stress into mononuclear cell activation(2003)913 cited
→ Effect of Linagliptin vs Glimepiride on Major Adverse Cardiovascular Outcomes in Patients With Type 2 Diabetes(2019)586 cited
→ Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease(2017)467 cited

→ The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus(2014)

465 cited

→ Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial(2017)367 cited

→ Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials(2019)357 cited

→ 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial(2012)336 cited